• Magneto-Piezoelectric Scaffolds Target Icam1+ Macrophages in

  2026-06-22

  This study pioneers the use of engineered magneto-piezoelectric nanoparticle-enhanced scaffolds to simultaneously disrupt bacterial biofilms and activate oxidative phosphorylation in Icam1+ macrophages, addressing the dual challenges of infection and impaired regeneration in bone defects. By modulating JAK2-STAT3 signaling, these scaffolds provide a new immunomodulatory strategy in tissue engineering.

• Standardized Whole-Blood Assays Reveal Metabolic Immune Modu

  2026-06-22

  This paper introduces a robust protocol for analyzing immune responses via standardized whole-blood stimulation combined with metabolic modulation. By systematically applying metabolic inhibitors, the study clarifies how cellular metabolism shapes cytokine production, offering a valuable methodological advance for immunometabolism research.

• Modulating Ionizable Lipids in LNPs for Organ-Selective mRNA

  2026-06-21

  This study introduces a multidimensional approach to designing ionizable lipids (ILs) for lipid nanoparticles (LNPs), significantly enhancing the efficiency and organ selectivity of mRNA delivery in vivo. By leveraging the Ugi four-component reaction, the authors rapidly generate structurally diverse IL libraries, enabling precise control over delivery tropism and efficacy—advancing rational design of mRNA therapeutics.

• Magneto-Piezoelectric Scaffolds Target JAK2-STAT3 in Bone Re

  2026-06-20

  This study introduces an engineered scaffold using magneto-piezoelectric nanoparticles to simultaneously disrupt bacterial biofilms and activate oxidative phosphorylation in Icam1+ macrophages via the JAK2-STAT3 pathway. The findings establish a new paradigm for treating infectious bone defects, combining immunometabolic modulation and infection control for enhanced tissue regeneration.

• GDC-0941: Precision PI3K Inhibitor in Translational Oncology

  2026-06-19

  GDC-0941 is redefining applied PI3K/Akt pathway inhibition, empowering cancer researchers to dissect resistance mechanisms and target stem-like cancer cells. This guide translates recent findings and robust experimental workflows into actionable protocols for high-impact oncology research.

• Acid-Responsive Nanomedicine Restores Stroma in Pancreatic C

  2026-06-19

  Fu et al. (2026) present a multistage, acid-responsive nanomedicine that sequentially remodels the dense stroma of pancreatic ductal adenocarcinoma, enabling improved gemcitabine penetration and significant tumor regression in vivo. This strategy advances the field by restoring stromal homeostasis rather than ablating the stroma, offering new translational avenues for overcoming chemoresistance.

• Harnessing Apicidin: Histone Deacetylase Inhibitor in Oocyte

  2026-06-18

  Apicidin is a selective histone deacetylase inhibitor that enables robust investigation of epigenetic regulation, tumor growth suppression, and reproductive toxicology. This article details advanced experimental workflows, key troubleshooting strategies, and cross-domain insights that maximize Apicidin's scientific impact.

• WP1066, JAK2/STAT3 Inhibitor: Antiproliferative Mechanisms &

  2026-06-18

  WP1066 is a potent, cell-permeable JAK2/STAT3 inhibitor that blocks phosphorylation and downstream oncogenic signaling. It induces apoptosis and antiproliferative effects in cancer cell models, with proven efficacy in renal carcinoma and acute myeloid leukemia research.

• Gepotidacin: Transforming Antibacterial Research via Novel T

  2026-06-17

  Explore how Gepotidacin, a first-in-class triazaacenaphthylene antibiotic, redefines antibacterial research through unique DNA gyrase and topoisomerase IV inhibition. Gain actionable insights for designing resistance studies and advanced bacterial pathway assays.

• Ionizable and PEGylated Lipids Dictate mRNA-LNP Potency In V

  2026-06-17

  This study systematically evaluates how different ionizable and pegylated lipids shape the potency of mRNA-loaded lipid nanoparticles (LNPs) in both in vitro and preclinical contexts. Findings reveal that while LNPs may share similar physical quality attributes, their in vivo efficacy and expression are highly dependent on specific lipid choices—offering crucial guidance for optimizing mRNA delivery systems.

• Palbociclib (PD0332991) Isethionate: Precision Tools for Tum

  2026-06-16

  Explore the advanced applications of Palbociclib (PD0332991) in tumor microenvironment modeling and personalized drug discovery. This article provides a deep scientific analysis and practical guidance for leveraging CDK4/6 inhibition in next-generation cancer research.

• Translating Src Kinase Inhibition: Mechanistic Rigor to Clin

  2026-06-16

  This thought-leadership article explores the mechanistic depth and translational promise of targeting Src family kinases with PP 2 (AG 1879), integrating new findings on cytoskeletal remodeling with strategic guidance for researchers. By bridging experimental rigor, competitive benchmarking, and clinical vision, it positions PP 2 as a cornerstone tool for next-generation cancer and immunology research.

• D-N-Acetylgalactosamine: Technical Protocols for Brain Glyco

  2026-06-15

  D-N-Acetylgalactosamine enables reproducible analysis of glycoprotein constituents in neurological research, specifically where high purity and defined solubility are essential. It is not suitable for workflows requiring ethanol solubility or long-term storage of working solutions. Strict adherence to handling and storage parameters prevents data loss and workflow interruptions.

• Trelagliptin Promotes Osteoblast Differentiation via RUNX2–A

  2026-06-15

  This study reveals that trelagliptin, a DPP-4 inhibitor, stimulates osteoblastic differentiation and mineralization in MC3T3-E1 cells by upregulating RUNX2 through AMPK activation. The findings highlight a novel therapeutic implication of trelagliptin in osteoporosis and establish a mechanistic link between diabetes medications and bone health.

• BCL-XL Inhibitor A-1155463: Applied Workflows in Cancer Rese

  2026-06-14

  A-1155463, a selective BCL-XL inhibitor, enables precision apoptosis induction and overcomes drug resistance in BCL-XL-dependent cancer models. This guide delivers practical workflow optimizations, troubleshooting tips, and actionable insights for deploying A-1155463 in translational oncology, leveraging the latest reference evidence and best-in-class product quality from APExBIO.

455 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page